NephroSant develops diagnostic tools for the early detection and continuous monitoring of kidney health using biomarker analysis and advanced imaging techniques. The company addresses the critical need for timely identification of kidney injury, enabling proactive management and improved patient outcomes.
Funding
$22.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting and monitoring kidney health often rely on late-stage indicators and invasive procedures, hindering early intervention and proactive management of kidney disease. The lack of timely and accurate diagnostic tools can lead to delayed treatment and poorer patient outcomes.
Solution
NephroSant is developing diagnostic tools designed for the early detection and continuous monitoring of kidney health. These tools leverage biomarker analysis and advanced imaging techniques to identify kidney injury at an earlier stage. By providing timely and accurate insights into kidney function, NephroSant aims to enable proactive management of kidney health and improve patient outcomes through earlier intervention.
Target Audience
The primary audience includes nephrologists, primary care physicians, and patients at risk for or with existing kidney disease.
Features
- Biomarker analysis for early detection of kidney injury
- Advanced imaging techniques for continuous monitoring of kidney health